Plant polyphenol curcumin significantly affects CYP1a2 and CYP2a6 activity in healthy, male Chinese volunteers

Annals of Pharmacotherapy

Volumn 44, Issue 6, 2010, Pages 1038-1045

  Chen, Yao ^a   Liu, Wen Hui ^a   Chen, Bi Lian ^a   Fan, Lan ^a   Han, Yang ^a   Wang, Guo ^a   Hu, Dong Li ^a   Tan, Zhi Rong ^a   Zhou, Gan ^a   Cao, Shan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Curcumin; CYP1A2; CYP2A6; NAT2; XO

Indexed keywords

1 METHYLURATE; 1 METHYLXANTHINE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CURCUMIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; PARAXANTHINE; UNCLASSIFIED DRUG; URATE; XANTHINE OXIDASE;

ADULT; ARTICLE; CHINESE; CURCUMA LONGA; DRUG EFFECT; DRUG EXCRETION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CAFFEINE; CROSS-OVER STUDIES; CURCUMIN; CYTOCHROME P-450 CYP1A2; DOWN-REGULATION; FLAVONOIDS; HERB-DRUG INTERACTIONS; HUMANS; MALE; PHENOLS; PLANT EXTRACTS; UP-REGULATION; YOUNG ADULT;

EID: 77952928396     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M533     Document Type: Article

References (45)

1. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75.
2. Chen J, Wanming D, Zhang D, Liu Q, Kang J. Water-soluble antioxidants improve the antioxidant and anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 2005;60:57-61.
3. Kalpana C, Menon VP. Curcumin ameliorates oxidative stress during nicotine-induced lung toxicity in Wistar rats. Ital J Biochem 2004;53:82-86
4. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 2003;9:161-168 (Pubitemid 36297021)
5. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005;224:53-65.
6. Duvoix A, Blasius R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005;223:181-190
7. Wang S, Chen B, Sun C. Regulation effect of curcumin on blood lipids and antioxidation in hyperlipidemia rats. Wei Sheng Yan Jiu 2000;29: 240-242
8. Kalpana C, Menon VP. Modulatory effects of curcumin on lipid peroxidation and antioxidant status during nicotine-induced toxicity. Pol J Pharmacol 2004;56:581-586 (Pubitemid 40123658)
9. Kuroda M, Mimaki Y, Nishiyama T, et al. Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 2005;28:937-939
10. Suryanarayana P, Saraswat M, Mrudula T, et al. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 2005;46:2092-2099
11. Li X, Liu X. Effect of curcumin on immune function of mice. J Huazhong Univ Sci Technolog Med Sci 2005;25:137-140
12. Taher MM, Lammering G, Hershey C, Valerie K. Curcumin inhibits ultraviolet light induced human immunodeficiency virus gene expression. Mol Cell Biochem 2003;254:289-297 (Pubitemid 37483764)
13. Hergenhahn M, Soto U, Weninger A, et al. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells. Mol Carcinog 2002;33:137-145 (Pubitemid 34195194)
14. Qureshi S, Shah AH, Ageel AM. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Medica 1992, 58:124-127
15. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. Indian J Exp Biol 1980;18:73-75
16. Walle T, Walle UK. Novel methoxylated flavone inhibitors of cytochrome P450 1B1 in SCC-9 human oral cancer cells. J Pharm Pharmacol 2007;59:857-862 (Pubitemid 47051098)
17. Choi H, Chun YS, Shin YJ, Ye SK, Kim MS, Park JW. Curcumin attenuates cytochrome P450 induction in response to 2,3,7,8-tetrachlorodibenzo-p-dioxin by ROS-dependently degrading AhR and ARNT. Cancer Sci 2008;99:2518-2524
18. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 2001;39:541-547 (Pubitemid 32429466)
19. Mori Y, Tatematsu K, Koide A, Sugie S, Tanaka T, Mori H. Modification by curcumin of mutagenic activation of carcinogenic N-nitrosamines by extrahepatic cytochromes P- 450 2B1 and 2E1 in rats. Cancer Sci 2006; 97:896-904.
20. Wu R, Cui X, Dong W, Zhou M, Simms HH, Wang P. Suppression of hepatocyte CYP1A2 expression by Kupffer cells via AhR pathway: the central role of proinflammatory cytokines. Int J Mol Med 2006;18:339-346
21. Price RJ, Scott MP, Giddings AM, et al. Effect of butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole on cytochrome P450 forms in cultured human hepatocytes. Xenobiotica 2008;38:574-586
22. Krizkova J, Burdova K, Hudecek J, Stiborova M, Hodek P. Induction of cytochromes P450 in small intestine by chemopreventive compounds. Neuro Endocrinol Lett 2008;29:717-721
23. Rinaldi AL, Morse MA, Fields HW, et al. Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7Rtrans-7,8- dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res 2002;62:5451-5456
24. Sugiyama T, Nagata J, Yamagishi A, et al. Selective protection of curcumin against carbon tetrachloride-induced inactivation of hepatic cytochrome P450 isozymes in rats. Life Sci 2006;78:2188-2193
25. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004;116:478-485 (Pubitemid 38388618)
26. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001;41:535-567
27. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98.
28. Wong P, Villeneuve G, Tessier V, et al. Stability of 5-acetamido-6- formylamino-3-methyluracil in buffers and urine. J Pharmaceut Biomed 2002;28:693-700.
29. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
30. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-127
31. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 2007;21:190-200.
32. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-165 (Pubitemid 17135971)
33. Chen Y, Xiao P, Ou-Yang DS, et al. The simultaneous effects of flavonoid quercetin on the activities of CYP1A2, CYP2A6, NAT2 and XO in healthy volunteers. Clin Exp Pharmacol Physiol 2009;36:828-833
34. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-473 (Pubitemid 24344037)
35. Eugster HP, Probst M, Würgler FE, Sengstag C. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab Dispos 1993;21:43-49 (Pubitemid 23052220)
36. Sinclair PR, Gorman N, Tsyrlov IB, Fuhr U, Walton HS, Sinclair JF. Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metab Dispos 1998;26:1019-1025 (Pubitemid 28478264)
37. Sweeney C, Coles BF, Nowell S, Lang NP, Kadlubar FF. Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer. Toxicology 2002;181-182:83-87 (Pubitemid 36015677)
38. Ishibe N, Sinha R, Hein DW, et al. Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 2002;12:145-150 (Pubitemid 34298918)
39. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev 2006;15:1812-1819 (Pubitemid 44664253)
40. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997;282:1608-1614
41. Nunoya KI, Yokoi T, Kimura K, et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3- pyridyl)thiazolidin- 4-one hydrochloride in humans. J Pharmacol Exp Ther 1999;289:437-442 (Pubitemid 29156060)
42. Nowell S, Sweeney C, Hammons G, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:377-383 (Pubitemid 34408217)
43. Chen Y, Tu JH, He YJ, et al. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers. Xenobiotica 2009;39:508-513
44. Christian K, Lang M, Maurel P, Raffalli-Mathieu F. Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. Mol Pharmacol 2004;65:1405-1414 (Pubitemid 38668299)
45. Raffalli-Mathieu F, Glisovic T, David YB, et al. Heterogeneous nuclear ribonucleoprotein A1 and regulation of the xenobiotic-inducible gene Cyp2a5. Mol Pharmacol 2002;61:795-799 (Pubitemid 34273159)